Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation
Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation
复制标题
DOI：
10.1002/lt.23687
复制
发表时间：
2013-09-01
影响因子：
4.6
通讯作者：
Klintmalm, Goeran B.
中科院分区：
文献类型：
--
作者：
O'Leary, Jacqueline G.;Kaneku, Hugo;Klintmalm, Goeran B.
预制的供体特异性人类白细胞抗原抗体（DSA）被认为是除肝脏以外的大多数实体器官移植的禁忌症。目前关于预制 DSA 在肝移植 (LT) 后排斥反应和患者生存中的重要性存在相互矛盾的数据。为了评估 LT 中预先进行的 DSA，我们回顾性分析了从 2000 年 1 月 1 日至 2009 年 5 月 31 日期间从所有未接受其他器官的原发性 LT 成年接受者中收集的样本，其中包括可用的 LT 前样本（95.8% 的患者）。 14% 的患者进行了 I 类和/或 II 类 DSA，平均荧光强度 (MFI) 为 5000。具有 MFI5000 的预制 I 类 DSA 仅在 5% 的患者中持续存在，并且与排斥反应无关。 23% 的患者持续进行 MFI 为 5000 至 10,000 的 II 类 DSA，对于 MFI 为 10,000 的患者，这一比例增加至 33%（P
Preformed donor-specific human leukocyte antigen antibodies (DSAs) are considered a contraindication to the transplantation of most solid organs other than the liver. Conflicting data currently exist on the importance of preformed DSAs in rejection and patient survival after liver transplantation (LT). To evaluate preformed DSAs in LT, we retrospectively analyzed prospectively collected samples from all adult recipients of primary LT without another organ from January 1, 2000 to May 31, 2009 with a pre-LT sample available (95.8% of the patients). Fourteen percent of the patients had preformed class I and/or II DSAs with a mean fluorescence intensity (MFI)5000. Preformed class I DSAs with an MFI5000 remained persistent in only 5% of patients and were not associated with rejection. Preformed class II DSAs with an MFI of 5000 to 10,000 remained persistent in 23% of patients, and this rate increased to 33% for patients whose MFI was 10,000 (P